Progenics Pharmaceuticals - 23 Year Stock Split History | PGNX

Stock split history for Progenics Pharmaceuticals since 1997. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Progenics Pharmaceuticals Annual Stock Splits
Progenics Pharmaceuticals Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.414B $0.016B
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $62.126B 11.33
Mylan (MYL) United States $11.272B 5.06
Teva Pharmaceutical Industries (TEVA) Israel $11.150B 4.54
Bausch Health Cos (BHC) Canada $10.295B 6.79
Dr Reddy's Laboratories (RDY) India $7.373B 19.43
ASPEN PHARMACR (APNHY) South Africa $3.515B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.248B 12.07
Amphastar Pharmaceuticals (AMPH) United States $0.926B 48.10
Homology Medicines (FIXX) United States $0.678B 0.00
Assembly Biosciences (ASMB) United States $0.438B 0.00
Voyager Therapeutics (VYGR) United States $0.436B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.410B 0.56
Sol-Gel Technologies (SLGL) Israel $0.249B 0.00
Akorn (AKRX) United States $0.196B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.148B 0.00
CymaBay Therapeutics (CBAY) United States $0.134B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.121B 0.00
Teligent (TLGT) United States $0.022B 0.00
China Pharma Holdings (CPHI) China $0.020B 0.00